Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability
R Davis, A Markham, JA Balfour - Drugs, 1996 - Springer
Ciprofloxacin is a broad spectrum fluoroquinolone antibacterial agent. Since its introduction
in the 1980s, most Gram-negative bacteria have remained highly susceptible to this agent in …
in the 1980s, most Gram-negative bacteria have remained highly susceptible to this agent in …
Oral administration of antibiotics: a rational alternative to the parenteral route
RR MacGregor, AL Graziani - Clinical Infectious Diseases, 1997 - academic.oup.com
Much early experience with antibiotic therapy involved oral administration of sulfonamides,
penicillins, tetracyclines, and chloramphenicol. Newer acid-labile, less-soluble agents …
penicillins, tetracyclines, and chloramphenicol. Newer acid-labile, less-soluble agents …
Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer
EB Rubenstein, K Rolston, C Escalante, E Manzullo… - Cancer, 1993 - Wiley Online Library
Background. Hospitalization and intravenous (IV) broad‐spectrum antibiotics are the
standard of care for all febrile neutropenic patients with cancer. Recent work suggests that a …
standard of care for all febrile neutropenic patients with cancer. Recent work suggests that a …
Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial
IA Malik, WA Khan, M Karim, Z Aziz, MA Khan - The American journal of …, 1995 - Elsevier
PURPOSE: We recently demonstrated the efficacy of single-agent oral ofloxacin in the
management of hospitalized neutropenic febrile patients. Ofloxacin was particularly effective …
management of hospitalized neutropenic febrile patients. Ofloxacin was particularly effective …
Review of the Incidence and Prognosis of Pseudomonas aeruginosa Infections in Cancer Patients in the 1990s
G Maschmeyer, I Braveny - European Journal of Clinical Microbiology and …, 2000 - Springer
In an attempt to determine the actual relevance of Pseudomonas aeruginosa as a target of
empiric antimicrobial first-line therapy in febrile cancer patients, 44 reports of clinical trials on …
empiric antimicrobial first-line therapy in febrile cancer patients, 44 reports of clinical trials on …
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients
L Vidal, M Paul, N Eliakim‐Raz… - Cochrane Database …, 2013 - cochranelibrary.com
Background Fever occurring in a neutropenic patient remains a common life‐threatening
complication of cancer chemotherapy. The common practice is to admit the patient to …
complication of cancer chemotherapy. The common practice is to admit the patient to …
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea
DG Lee, SH Kim, SY Kim, CJ Kim… - Infection & …, 2011 - synapse.koreamed.org
Neutrophils play an important role in immunological function. Neutropenic patients are
vulnerable to infection, and except fever is present, inflammatory reactions are scarce in …
vulnerable to infection, and except fever is present, inflammatory reactions are scarce in …
New trends in patient management: risk-based therapy for febrile patients with neutropenia
KVI Rolston - Clinical infectious diseases, 1999 - academic.oup.com
Standard management of febrile neutropenia includes the prompt administration of
empirical, broad-spectrum, parenteral antibiotic therapy. This is generally done in a hospital …
empirical, broad-spectrum, parenteral antibiotic therapy. This is generally done in a hospital …
Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients
IA Malik, Z Abbas, M Karim - The Lancet, 1992 - Elsevier
Prompt treatment with empirical antibiotics in neutropenic febrile patients reduces morbidity
and mortality. Most patients have been treated with parenteral combination antibiotics, but …
and mortality. Most patients have been treated with parenteral combination antibiotics, but …
Risk assessment and treatment of low-risk patients with febrile neutropenia
WV Kern - Clinical infectious diseases, 2006 - academic.oup.com
Progress has been made in the development and validation of rules that attempt ito predict a
low risk (< 10%) of severe infection or clinical complications in patients with cancer, fever …
low risk (< 10%) of severe infection or clinical complications in patients with cancer, fever …